NCT05727163View on ClinicalTrials.gov

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Dexamethasone

25mg via HAI (Pre-chemotherapy)

DRUG

Anisodamine

10 mg via HAI (Pre-chemotherapy)

DRUG

Oxaliplatin

85 mg/m2 via HAI over 3 hours

DRUG

Leucovorin

200 mg/m2 via HAI

DRUG

Fluorouracil

400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours

DRUG

Irinotecan

150 mg/m2 intravenously

DRUG

Bevacizumab

5 mg/kg intravenously

DRUG

Oxaliplatin

85 mg/m2 intravenously over 3 hours

DRUG

Leucovorin

200 mg/m2 intravenously

DRUG

Fluorouracil

400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER